Year: 2024
Type: editorial
Abstract: In this issue of Blood, Pipe et al 1 report on the high safety and efficacy of emicizumab, a recombinant, humanized, bispecific monoclonal antibody, in children <1 year of age with severe hemophilia A (HA) (<1% factor VIII [FVIII]) and without FVIII antibodies (inhibitors).This novel, practice-changing, largestudy finding, not reported previously in the infant age group, is described in this multicenter, phase 3b, open-label, single-arm study.Long-term data will be collected over the next 7 years.
Source: Blood
Author: Thomas C. Abshire
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4393931487